The above findings highlight the importance of TRPV1, TRPA1 and TRPC5 as modulators of inflammation in MS and are supported by studies performed with their endogenous agonists, including H2O2, 4-HNE and reduced TRX. Here, TRPC5 is linked to myeloid sarcoma.